A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
- 24 May 1999
- Vol. 24 (6) , 603-609
- https://doi.org/10.1016/s8756-3282(99)00087-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological VariabilityJournal of Bone and Mineral Research, 1998
- Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeNew England Journal of Medicine, 1998
- Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral DensityThe American Journal of Medicine, 1997
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosisJournal of Bone and Mineral Research, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatmentJournal of Clinical Endocrinology & Metabolism, 1994
- Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone diseaseJournal of Clinical Endocrinology & Metabolism, 1993
- The impact of measurement errors on the diagnostic value of bone mass measurements: Theoretical considerationsOsteoporosis International, 1991
- Screening procedure for women at risk of developing postmenopausal osteoporosisOsteoporosis International, 1990
- Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal womenEuropean Journal of Clinical Investigation, 1988